Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,325.00
Bid: 1,322.00
Ask: 1,327.00
Change: -3.00 (-0.23%)
Spread: 5.00 (0.378%)
Open: 1,325.00
High: 1,331.00
Low: 1,297.00
Prev. Close: 1,328.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SID & Chair of Remuneration Committee

16 Feb 2023 15:00

RNS Number : 1944Q
Indivior PLC
16 February 2023
 

February 16, 2023

 

Senior Independent Director & Chair of Remuneration Committee

 

 

Indivior PLC (the "Company") today announces that Juliet Thompson has been appointed as Senior Independent Director with effect from October 1, 2023. Juliet has been a Non-Executive Director since March 2021 and is the Chair of the Audit Committee and a member of the Nomination & Governance Committee.

 

The Company further announces that Jo Le Couilliard has been appointed as Chair of the Remuneration Committee also with effect from October 1, 2023. Jo has been a Non-Executive Director since March 2021 and is a member of the Audit and Remuneration Committees.

 

This announcement follows the Company's previous announcement on October 13, 2022 that Daniel J. Phelan, current Senior Independent Director and Chair of the Remuneration Committee, will stand down from the Board on September 30, 2022 having served as a Director for nine years.

 

This announcement is made pursuant to Listing Rule 9.6.11.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in 39 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

For Further Information

 

Jason Thompson

VP, Investor Relations

Indivior PLC

+1 804 402 7123

jason.thompson@indivior.com

Tim Owens

Director, Investor Relations Indivior PLC

+1 804 263 3978

timothy.owens@indivior.com

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEALAKFAADEFA
Date   Source Headline
13th Dec 20227:00 amRNSTransaction in Own Shares
12th Dec 20227:00 amRNSTransaction in Own Shares
9th Dec 20221:04 pmRNSHolding(s) in Company
9th Dec 20227:00 amRNSTransaction in Own Shares
8th Dec 20227:00 amRNSTransaction in Own Shares
7th Dec 20227:00 amRNSIndivior Dec. 7 Capital Markets Day Highlights
7th Dec 20227:00 amRNSTransaction in Own Shares
6th Dec 20227:00 amRNSTransaction in Own Shares
5th Dec 20224:12 pmRNSHolding(s) in Company
5th Dec 20222:05 pmRNSSharesave Grant
5th Dec 20227:00 amRNSTransaction in Own Shares
2nd Dec 202212:27 pmRNSHolding(s) in Company
2nd Dec 20227:00 amRNSTransaction in Own Shares
1st Dec 20229:25 amRNSTotal Voting Rights
1st Dec 20227:00 amRNSTransaction in Own Shares
30th Nov 20223:32 pmRNSHolding(s) in Company
30th Nov 20227:00 amRNSTransaction in Own Shares
29th Nov 20227:00 amRNSTransaction in Own Shares
28th Nov 202212:05 pmRNSHolding(s) in Company
28th Nov 20227:00 amRNSTransaction in Own Shares
25th Nov 20227:00 amRNSTransaction in Own Shares
24th Nov 20227:00 amRNSTransaction in Own Shares
23rd Nov 20224:25 pmRNSHolding(s) in Company
23rd Nov 20227:00 amRNSTransaction in Own Shares
22nd Nov 20222:36 pmRNSHolding(s) in Company
22nd Nov 20222:32 pmRNSHolding(s) in Company
22nd Nov 20227:00 amRNSTransaction in Own Shares
21st Nov 20227:00 amRNSTransaction in Own Shares
18th Nov 20227:00 amRNSTransaction in Own Shares
17th Nov 20227:00 amRNSTransaction in Own Shares
16th Nov 20227:00 amRNSTransaction in Own Shares
15th Nov 202210:00 amRNSDirector Declaration
15th Nov 20227:00 amRNSTransaction in Own Shares
14th Nov 20227:00 amRNSIndivior To Acquire Opiant Pharmaceuticals
14th Nov 20227:00 amRNSTransaction in Own Shares
11th Nov 20227:00 amRNSTransaction in Own Shares
10th Nov 20227:00 amRNSTransaction in Own Shares
9th Nov 20224:46 pmRNSBlock listing Interim Review
9th Nov 20228:30 amRNSIndivior to Host Capital Markets Day December 7
9th Nov 20227:00 amRNSTransaction in Own Shares
8th Nov 202210:48 amRNSHolding(s) in Company
8th Nov 20227:00 amRNSTransaction in Own Shares
7th Nov 20227:00 amRNSTransaction in Own Shares
4th Nov 20227:00 amRNSTransaction in Own Shares
3rd Nov 20227:00 amRNSTransaction in Own Shares
2nd Nov 20227:00 amRNSTransaction in Own Shares
1st Nov 20229:28 amRNSTotal Voting Rights
1st Nov 20229:08 amRNSIndivior to Participate in Conference
1st Nov 20227:00 amRNSTransaction in Own Shares
31st Oct 20227:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.